Crinetics Pharmaceuticals CRNX
CRNX
$84.95 +0.00 (+0.00%)
At close: Sep 2, 2026 · 4:00 PM EDT

Crinetics Pharmaceuticals (CRNX) Gains from Sales and Divestitures (2023 - 2026)

Updated

Crinetics Pharmaceuticals (CRNX) recorded Gains from Sales and Divestitures of -$20,000 in Q1 2026, compared with -$19,000 a year earlier.

Analysis

Crinetics Pharmaceuticals (CRNX) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends

For FY2025, Crinetics Pharmaceuticals reported Gains from Sales and Divestitures of -$50,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$51,000 in FY2024 and -$6,000 in FY2023.
  • Quarterly Gains from Sales and Divestitures has ranged from -$42,000 in Q1 2024 to -$6,000 in Q2 2023 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Crinetics Pharmaceuticals 8.99 Bn 8.99 Bn 24.96 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -20,000.00
Dec 31, 2025 -8,000.00
Jun 30, 2025 -23,000.00
Mar 31, 2025 -19,000.00
Sep 30, 2024 -9,000.00
Mar 31, 2024 -42,000.00
Jun 30, 2023 -6,000.00
API Access

Crinetics Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRNX&period=max&api_key=YOUR_API_KEY